Aflibercept (Synonyms: VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1) |
| Catalog No.GC68628 |
Aflibercept는 고친화성 솔러블 디코이 동맥 내피 성장 인자(VEGF) 수용체이고 강력한 혈관 생성 억제제로 동맥 내피 성장 인자와 태반 성장 인자(PlGF)를 경력한 혈관신생 억제제 결합할 수 있다. 전신적 연구는 Aflibercept가 흑색종과 고형 종양을 포함한 다양한 종양에 대해 강력한 항종양 및 항혈관 생성 활동을 보인다고 보여 준다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 862111-32-8
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Aflibercept는 고친화성 솔러블 디코이 동맥 내피 성장 인자(VEGF) 수용체이고 강력한 혈관 생성 억제제로 동맥 내피 성장 인자와 태반 성장 인자(PlGF)를 경력한 혈관신생 억제제 결합할 수 있다. 전신적 연구는 Aflibercept가 흑색종과 고형 종양을 포함한 다양한 종양에 대해 강력한 항종양 및 항혈관 생성 활동을 보인다고 보여 준다.
Aflibercept (7.5μg/ml; 10분)는 갤렉틴-1에 의한 VEGFR2 활성을 억제한다[2]. Aflibercept (15nM; 1시간)는 ARPE-19와 HUVEC의 세포 표면 결합이 현저하지 않는다. Aflibercept (500nM; 10-15분)는 헹신의 존재하에 세로토닌의 방출을 자극할 수 없다[3].
Aflibercept (10mg/kg와 25mg/kg; SC; 매주 두 번; 30일)는 기초 종양 성장을 74%와 78%로 억제하고 검출 가능한 폐 전이 형성을 98%의 경우에 억제한다[4]. Aflibercept (10mg/kg; 3시간)는 중풍으로 인한 VEGF-A와 VEGFR2의 표현을 줄이고 뇌수종과 혈뇌 장벽의 파괴를 완화하고 중풍 후 중뇌동맥 폐색(MCAO) 후 비만 쥐의 생존율을 향상시킬 수 있다[5].
References:
[1] Bender J G, Blaney S M, Borinstein S, et al. A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report[J]. Clinical cancer research, 2012, 18(18): 5081-5089.
[2] Kanda A, Noda K, Saito W, Ishida S. Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy. Sci Rep. 2015 Dec 9;5:17946.
[3] MacDonald DA, Martin J, Muthusamy KK, Luo JK, Pyles E, Rafique A, Huang T, Potocky T, Liu Y, Cao J, Bono F, Delesque N, Savi P, Francis J, Amirkhosravi A, Meyer T, Romano C, Glinka M, Yancopoulos GD, Stahl N, Wiegand SJ, Papadopoulos N. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes. Angiogenesis. 2016 Jul;19(3):389-406.
[4] Moroney JW, Sood AK, Coleman RL. Aflibercept in epithelial ovarian carcinoma. Future Oncol. 2009 Jun;5(5):591-600.
[5] Kim ID, Cave JW, Cho S. Aflibercept, a VEGF (Vascular Endothelial Growth Factor)-Trap, Reduces Vascular Permeability and Stroke-Induced Brain Swelling in Obese Mice. Stroke. 2021 Aug;52(8):2637-2648.
| 세포 실험 [1]: | |
세포 라인 | 인간 RPE (hTERT-RPE1) 세포 |
제조 방법 | 인간 RPE (hTERT-RPE1) 세포는 Aflibercept (7.5μg/ml)로 10분 동안 처리되었습니다. |
반응 조건 | Aflibercept: 7.5μg/ml; 10분 동안 |
응용 분야 | Aflibercept (7.5μg/ml; 10분)는 갤렉틴-1에 의한 VEGFR2 활성을 억제합니다. |
| 동물 실험 [2]: | |
동물 모형 | 원위 쥐 신장암 세포 모델 |
제조 방법 | Aflibercept 10mg/kg와 25mg/kg은 용매 대조군에 비해 매주 두 번 피하 주사로 최대 30일 동안 투여되었습니다. |
제형 | 10 및 25mg/kg; SC; 매주 두 번; 30일 동안 |
응용 분야 | Aflibercept (10mg/kg와 25mg/kg; SC; 매주 두 번; 30일)는 기초 종양 성장을 74%와 78%로 억제하고 검출 가능한 폐 전이 형성을 98%의 경우에 억제했습니다. |
References: | |
| Cas No. | 862111-32-8 | SDF | |
| Synonyms | VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1 | ||
| Formula | M.Wt | ||
| Solubility | Storage | Sealed and stored at ≤ -30°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >97.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *